IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: Ten years too late?

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 74-78

  Jensen, Donald M ^a   Pol, Stanislas ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Université Paris Descartes ^*  (France)

Author keywords

Antiviral; Genome wide association studies; Hepatitis C; IL28B; Interferon; Ribavirin; Treatment

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; CLINICAL TRIAL; GENOTYPE; HEPATITIS C; HUMAN; MEDICAL DECISION MAKING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; PATIENT SELECTION; POLYMORPHISM, GENETIC; SERINE PROTEINASE INHIBITORS;

EID: 84855223273     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02712.x     Document Type: Review

References (28)

1. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
2. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
3. Diago M, Castellano G, Garcia-Samaniego J, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55: 374-9.
4. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
5. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
6. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
7. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
8. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
9. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
10. Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Aids 2010; 24: F23-9.
11. Lange CM, Moradpur D, Doehring A, et al. Impact of donor and recipient ILB rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-7.
12. Morrow MP, Pankhong P, Laddy DJ, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113: 5868-77.
13. Kotenko SV, Gallgher E, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
14. Sheppard P, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
15. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-98.
16. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 1043-54.
17. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-31.
18. Asselah T, Bièche I, Narguet S, et al. Liver Gene Expression Signature to Predict Response to Pegylated interferon plus Ribavirin combination therapy in Patients with Chronic Hepatitis C. Gut 2008; 57: 516-24.
19. Freeman AJ, Pan Y, Harvey CE, et al. The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. J Hepatol 2003; 38: 349-56.
20. Bochud P, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor HCV clearance are protective against liver necroinflammatory activity and fibrosis progression in patients infected with non-1 HCV genotypes. Hepatology 2011 [epub ahead of print].
21. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; in press.
22. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.
23. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
24. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
25. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
26. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
27. Marcellin P, Jacobson IM, Zeuzem S, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial. J Hepatol 2011; 54: S183-4.
28. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study [Abstract]. J Hepatol 2011; 54(Suppl. 1): S6.